LAG-3 Antibody [2A11] | SD8837

LAG-3 Antibody [2A11] | SD8837 | Gentaur UK, US & Europe Distribution

Host: Llama

Reactivity: Human

Homology: N/A

Immunogen: LAG3 antibody was raised against a recombinant protein corresponding to amino acids 23-434 of human LAG3.

Research Area: Immunology

Tested Application: E, IHC-P, IF, Flow

Application: LAG-3 antibody can be used for ELISA starting at 0.1 μg/mL. For immunohistochemistry starting at 1 μg/mL. For immunofluorescence start at 5 μg/mL. For flow cytometry at 1 μg/ml.

Specificiy: N/A

Positive Control 1: N/A

Positive Control 2: N/A

Positive Control 3: N/A

Positive Control 4: N/A

Positive Control 5: N/A

Positive Control 6: N/A

Molecular Weight: N/A

Validation: N/A

Isoform: N/A

Purification: LAG3 Antibody is affinity chromatography purified via Nickel column. Antibody is supplied as a His-tagged purified protein.  It also contains a myc-tag for detection.

Clonality: Recombinant Monoclonal

Clone: 2A11

Isotype: sdAb

Conjugate: Unconjugated

Physical State: Liquid

Buffer: LAG-3 Antibody is supplied in PBS.

Concentration: 1 mg/mL

Storage Condition: LAG3 antibody should be stored in working aliquots at -20˚C, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.

Alternate Name: LAG3 Antibody: lymphocyte activating 3, LAG-3, CD223

User Note: Optimal dilutions for each application to be determined by the researcher.

BACKGROUND: The lymphocyte activation gene-3 (LAG3) is a member of the immunoglobulin superfamily and binds MHC class II with high affinity (1), negatively regulating T-cell function and homeostasis (2). It is expressed in B, T, and NK cells, monocytes, and dendritic cells (3), and acts to regulate T cell expansion (4). LAG3 is also an important immune checkpoint protein, with anti-LAG3 antibodies activating T effector cells and affecting regulatory T cell functions. Furthermore LAG3 appears to act in a synergistic fashion with PD-1/PD-L1, suggesting that a dual antibody approach may prove useful in cancer immunotherapy.